However, previous studies showed that in mouse models of AD, hippocampal expression of FGF2, mediated by a viral vector, improves memory function, enhances long-term potentiation in the CA1 region and reduces Aβ levels [90], indicating a potential for the use of FGF2 as a therapeutic agent for AD. The gene discussed is FGF2; the disease is Alzheimer disease.